Chronic plaque psoriasis
Credit: DermNet
A recent scientific investigation published in JID Innovations examined the structural composition of IL-23-binding epitopes to better understand how their molecular properties relate to the clinical efficacy of IL-23 inhibitors for the treatment of plaque psoriasis. Daniele et al investigated risankizumab, tildrakizumab, and guselkumab, which bind the IL-23 p19 subunit, as well as ustekinumab, which binds the IL-23 p40 subunit.1
The study was conducted in the research lab of Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine in New Haven, Connecticut, and Dermatology Times Winter Editor in Chief.
This was a very exciting study to perform because of its direct translational impact connecting science to the clinic. Having prescribed IL-23 biologics for years for patients with psoriasis, I needed to know how and why they were similar or different mechanistically. I thought this information could benefit providers and patients, Bunick told Dermatology Times.
Overall, the study authors found that each IL-23 inhibitor binds an epitope with a unique size, composition, and location except for a 10-residue overlap region outside of the IL-23 receptor epitope. The data provides a molecular explanation for why risankizumab demonstrated the highest efficacy in PASI90 responses among IL-23 inhibitors studied by network meta-analysis.
Background
According to Daniele et al, the IL-23 cytokine is a heterodimer made of the p19 and p40 subunits, which bind IL-23 receptor (IL-23R) and IL12R1 coreceptors to activate canonical IL-23 signaling. The study authors noted that p19 is unique to IL-23 and p40 is found in other cytokines, including IL-12.
Risankizumab, tildrakizumab, and guselkumab perform differently than ustekinumab due to their specific binding to p19, unlike ustekinumabs binding to p40, which enables both anti-IL-23 and anti-IL-12 activity. Through binding to these distinct subunits, the IL-23-targeted inhibitors and ustekinumab exert their therapeutic function by interrupting specific subunit/coreceptor interactions, wrote Daniele et al.
Previous studies by the Bunick lab2 analyzed the binding sites and epitopes of TNF-, IL-17, and IL-23 inhibitors to identify the molecular differences among the epitopes of different therapeutics in each biologic class; however, IL-23 analyses were limited to ustekinumab at the time due to a lack of data for other biologics. Daniele et al conducted their recent analysis to address the gap in knowledge of the structural mechanisms of action of the p19-specific IL-23 inhibitors in clinical use.
Methods
Daniele et al used epitope data from hydrogen-deuterium exchange studies for risankizumab, tildrakizumab, and guselkumab, and used crystallographic data for ustekinumab to map epitope locations, hydrophobicity, and surface charge onto the surface of the IL-23 crystal structure.
The molecular properties of each inhibitor epitope, including solvent-accessible surface area (SA), were correlated to binding affinity, kinetic values, and clinical efficacy scores for plaque psoriasis through linear regression analysis.
Composite short-term (10 to 16 weeks) and long-term (44 to 60 weeks) PASI90 response rate data were obtained from a network meta-analysis performed by Armstrong et al3, and inhibitor equilibrium dissociation constant (KD), dissociation rate constant (koff), and association rate constant (kon) were obtained from Zhou et als IL-23 antibodies comparative study.4
Results
Each biologic epitope and IL-23R-binding site were mapped onto the molecular surface of IL-23 to compare binding mechanisms. Risankizumab has the largest epitope SA, followed by guselkumab. Ustekinumab and tildrakizumab bind a much smaller epitope SA. Daniele et al determined that p19-specific inhibitor epitopes have different locations, as guselkumab had the most overlap with the IL-23R-binding site. Guselkumab overlaps with 58% of residues of the IL-23R epitope; risankizumab overlaps with 8% of residues; and tildrakizumab overlaps with 0% of residues.
One region exists in the IL-23 p19 sequence where all 3 epitopes overlap: 10 residues from S114-Q123 (SLLPDSPVGQ). Importantly, this area does not overlap with the IL-23R-binding site, suggesting that steric effectsrather than direct competition for the receptor-binding siteare sufficient to disrupt IL-23R binding, wrote the study authors.
Looking at chemical compositions, Daniele et al found that the IL-23 inhibitors epitopes had a greater hydrophobic character than the IL-23R-binding site (32% hydrophobic). Tildrakizumab had a 56% hydrophobic solvent accessible SA, while guselkumab, risankizumab, and ustekinumab had epitopes with greater than 50% non-hydrophobic residues. Regarding p19 epitopes, risankizumab was the only inhibitor with a strongly acidic surface charge. The p40 epitope of ustekinumab had a strongly acidic epitope.
When analyzing whether each inhibitors epitope SA correlated with its previously reported binding affinity and kinetic values, Daniele et al found an inverse relationship between epitope SA and an inhibitors KD, indicating that increased epitope SA correlates with higher epitope-binding affinity. Individual epitope SA was inversely correlated with an inhibitors koff, however, the same correlation was not found between epitope SA and kon, suggesting a larger SA creates more stable immune complexes with IL-23, which according to Bunick, those complexes do not like to separate (a lower off rate).
A 2020 meta-analysis comparing IL-23 inhibitor efficacy showed that risankizumab had the highest PASI90 response rates, followed by guselkumab and ustekinumab. Tildrakizumab had a lower PASI90 response rate after 10 to 16 weeks (short-term). Daniele et al compared the 2020 meta-analysis data with the structural properties of each inhibitor epitope identified in their analyses to better understand the connection between epitope structure and clinical response for IL-23 inhibitors.
Daniele et al found a significant correlation between epitope SA of each biologic and short-term PASI90 rates. With higher epitope SA, risankizumab and guselkumab had the higher short-term PASI90 response rates, while tildrakizumab with the smallest epitope SA had the lowest PASI90 response rates.
Ustekinumab fits within this trend, indicating that ustekinumabs dual IL-12/IL-23 inhibition may not cause it to behave differently from the targeted IL-23 inhibitors in the short-term; rather, its initial efficacy may be due to the size of its epitope SA, wrote Daniele et al. The study authors also found that increased binding affinity translated to higher PASI90 response rates, and koff was strongly correlated with PASI90 rates compared to kon, indicating that slower dissociation of biologic-IL-23 complex leads to more effective treatment of plaque psoriasis.
While analyzing whether IL-23 inhibitor epitope SA, KD, and koff correlated with long-term PASI90 responses, Daniele et al found a strong correlation between epitope SA of each biologic and long-term (44 to 60 weeks) PASI90 rates. Inhibitor KD and koff were also associated with long-term PASI90 rates. There was no statistically significant relationship found between PASI90 rates and kon.
Key Takeaways
Based on their findings, Daniele et al determined that molecular differences between p19-specific psoriasis biologics directly relate to patient outcomes. The strong correlations found between inhibitor epitope SA, binding affinity, dissociation kinetics, and PASI90 response rates show how biochemical and molecular data are needed to explain clinical observations, according to the study authors.
Our analyses suggest that the size/SA of the IL-23 inhibitor epitope is an important structural parameter in defining and explaining both short- and long-term therapeutic response for IL-23 biologics in plaque psoriasis treatment, more than total residue hydrophobicity, polarity, or charge content... Our data ultimately indicate that epitope SA has a major influence on stable drug-target complex formation and preventing biologic-IL-23 dissociation, which mitigates aberrant IL-23 signaling central to psoriasis pathophysiology, wrote Daniele et al.
Based on their analyses, the study authors stated that their work increases the molecular understanding of IL-23 inhibitors by characterizing and differentiating the chemistry and structure of binding epitopes. Their data also confirms that direct IL-23 inhibitor epitope overlap with the IL-23R epitope is not needed for clinical efficacy due to risankizumabs and tildrakizumabs clinically meaningful PASI90 response rates, even with low epitope overlap with IL-23R.
Considering other biologic classes, Our findings regarding the relationship between epitope size/SA, koff, and clinical efficacy in plaque psoriasis are not unique to IL-23 inhibitors but instead appear to be shared with other biologic classes such as the IL-17 inhibitors: ixekizumab (IXE) and secukinumab (SEC). As reported by Warren et al, a greater proportion of patients with moderate-to-severe plaque psoriasis achieved PASI90 and PASI100 within 12 weeks of therapy with IXE in contrast to therapy with SEC as demonstrated by indirect comparison, wrote Daniele et al.
Daniele et als findings of the relationship between the structural properties of IL-23 inhibitor epitopes and clinical efficacy provide clinicians with molecular rationale for therapeutic selection, according to the study authors. Their analysis shows that each p19-specific therapeutic is molecularly distinct, suggesting that a lack of clinical response in one IL-23 inhibitor does not mean that the others will not demonstrate a clinical response.
Future studies aggregating both short-term and long-term data for all IL-23 biologics in the treatment of plaque psoriasis will be necessary to provide a more complete understanding of the structural properties of inhibitor epitopes and their clinical responses, concluded Daniele et al.
References
View post:
- American Academy of Dermatology Association Statement on Reports on Counterfeit Injectables - Newswise - April 15th, 2024 [April 15th, 2024]
- Atopic Dermatitis (Eczema): 5 Top Self-Care Tips - Everyday Health - April 15th, 2024 [April 15th, 2024]
- Derm In The News: April 7-13 - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Generative models improve fairness of medical classifiers under distribution shifts - Nature.com - April 15th, 2024 [April 15th, 2024]
- A 30-Year-Old White Female Presented With a 4-Month History of Scaly, Erythematous Patches and Plaques on Her ... - MDedge - April 15th, 2024 [April 15th, 2024]
- 9 Best Baby Eczema Creams of 2024 to Soothe Delicate Skin, According to Dermatologists - Allure - April 15th, 2024 [April 15th, 2024]
- QUIZ: Test Your Knowledge of Rosacea Etiology, Types, and Triggers - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Empowering Patients: Effective Dermatologic Treatment Selection for Hand and Feet AD - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- How To Treat Strawberry Legs, According To Dermatologists - Women's Health - April 15th, 2024 [April 15th, 2024]
- Rosacea Awareness Month: Resources to Share With Your Patients - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Understanding Drug Interactions in Systemic Treatment: Impact on Atopic Dermatitis Symptoms - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Derm In The News: March 31-April 6 - Dermatology Times - April 7th, 2024 [April 7th, 2024]
- Dr. Hillary Johnson-Jahangir of Forefront Dermatology Designated as a Candela Center of Excellence - PR Newswire - April 7th, 2024 [April 7th, 2024]
- How to Boost Your Immune System While Living With Psoriasis - Everyday Health - April 7th, 2024 [April 7th, 2024]
- Im a Harvard-trained dermatologist Ive followed 3 anti-aging rules for years, Im still a fan of a drug... - The US Sun - April 7th, 2024 [April 7th, 2024]
- Cosmetic Procedures for Psoriasis: Are They Safe? - Everyday Health - April 7th, 2024 [April 7th, 2024]
- FDA Approves Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum - Dermatology Times - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - The Mountaineer - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - Islander News.com - January 8th, 2024 [January 8th, 2024]
- How To Get Rid Of Dark Spots On Your Face, Per Dermatologists - Women's Health - January 8th, 2024 [January 8th, 2024]
- POLL: What Are Your 2024 Dermatology Resolutions? - Dermatology Times - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - NBC Right Now - January 8th, 2024 [January 8th, 2024]
- Common perianal diseases and dermatology oddities - DVM 360 - January 8th, 2024 [January 8th, 2024]
- How To Keep Skin Hydrated And Protected In The Cold According To Dermatologists - Essence - January 8th, 2024 [January 8th, 2024]
- Retinol and Retinoids: 9 Things You Should Know Before Using - Vogue - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - pdclarion.com - January 8th, 2024 [January 8th, 2024]
- 8 Wintertime Skin Conditions to Look Out For - Health.com - January 8th, 2024 [January 8th, 2024]
- 9 Tips for Common Winter Skin Conditions, According to a Celeb Dermatologist - PEOPLE - January 8th, 2024 [January 8th, 2024]
- FDA Approval of ZELSUVMI Berdazimer Gel: A Revolutionary Achievement | Health News - Medriva - January 8th, 2024 [January 8th, 2024]
- Revolutionary Research Towards Acne Vaccine and Gene Editing Treatments - Medriva - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - Corydon Times - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - Hometown Register - January 8th, 2024 [January 8th, 2024]
- Rice Water for Hair Growth: Does It Really Work? - Health.com - January 8th, 2024 [January 8th, 2024]
- Dermatology Times 2023 In Review: NP and PA News - Dermatology Times - December 31st, 2023 [December 31st, 2023]
- Colorado dermatology company warning about cybersecurity threat where hacker gained access to health information - Summit Daily - December 31st, 2023 [December 31st, 2023]
- Reviewing the Top Dermatology Headlines of 2023 - Dermatology Times - December 31st, 2023 [December 31st, 2023]
- Dermatology Times 2023 In Review: Acne - Dermatology Times - December 31st, 2023 [December 31st, 2023]
- Skin to Skin: Getting to know UMs new dermatology club - The Miami Hurricane - December 22nd, 2023 [December 22nd, 2023]
- Advancements in Atopic Dermatitis: Insights from the 2024 Masterclasses in Dermatology Conference - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- Schweiger Dermatology Group Acquires New Jersey Practices of NavaDerm Partners in Millburn and Englewood Cliffs - PR Newswire - December 22nd, 2023 [December 22nd, 2023]
- Spike in dermatology visits for skin problems seen during summer of wildfires - Medical Xpress - December 22nd, 2023 [December 22nd, 2023]
- More Images of Patients With Psoriasis Are Needed in Published Studies - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- Case Based Roundtables Part 2: Valorizing Topical Treatment Options for Patients With Vitiligo - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- Practical Approaches to Atopic Dermatitis: Real-World Case Analyses - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- Schweiger Dermatology Group Expands into South Florida with Locations in West Palm Beach and Miami Beach - Tullahoma News and Guardian - December 22nd, 2023 [December 22nd, 2023]
- Receding Hairline: Symptoms, Causes, Treatments - Men's Health - December 22nd, 2023 [December 22nd, 2023]
- Podcast CE: Ophytrium in Dermatology: When, where and whys of using Douxo S3 topical therapies - DVM 360 - December 22nd, 2023 [December 22nd, 2023]
- POLL: Which Skin Cancer Drug Recently Received a Complete Response Letter From the FDA? - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- How to Treat Textured Skin, According to Dermatologists - Prevention Magazine - December 22nd, 2023 [December 22nd, 2023]
- Dermatology decoded with Dr. Davin Lim - manilastandard.net - December 22nd, 2023 [December 22nd, 2023]
- Arcutis' Zoryve bags 2nd FDA nod, this time as a foam to treat 'the great neglected disease in dermatology' - FiercePharma - December 22nd, 2023 [December 22nd, 2023]
- Moderna and Merck's V940 Plus Pembrolizumab Demonstrates Improvement in RFS and DMFS in Stage III/IV ... - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- From customised vitamin infusions to tech-driven dermatology: Skincare trends that dominated 2023 - The Indian Express - December 22nd, 2023 [December 22nd, 2023]
- Aptar Digital Health and Legit.Health Partner to Improve Patient Experience in Immuno-Dermatology - Healthcare Packaging - December 22nd, 2023 [December 22nd, 2023]
- Navigating Location Specific Treatment Selection and Topical Therapy Limitations - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- POLL: What Percent of the Global Population is Estimated to Have ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Purple Heart Project Seeks to Provide Veterans With Access to ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Dermatology expert stresses importance of cytology and cultures - DVM 360 - November 18th, 2023 [November 18th, 2023]
- Shawn Kwatra, MD, Shares Highlights From the 12th World ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- The Weekly Roundup: November 12-17 - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Almirall, Absci Partner to Develop AI-Designed Therapies for ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- The Skin of Color Society Kicks Off a Season of Giving with its My ... - PR Newswire - November 18th, 2023 [November 18th, 2023]
- Clascoterone Cream in Patients With Acne: New Long-Term Data - Medpage Today - November 18th, 2023 [November 18th, 2023]
- Discovery of hemoglobin in the epidermis sheds new light on our ... - EurekAlert - November 18th, 2023 [November 18th, 2023]
- Global Assessment of Quality of Care for Patients With Malignant ... - Dermatology Advisor - November 18th, 2023 [November 18th, 2023]
- Effective Therapies for Atopic Dermatitis: Expert Recommendations ... - HealthDay - November 18th, 2023 [November 18th, 2023]
- Nonablative Lasers Offer a Gentle Approach to Healthy Skin - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Aging, Acne, and the Armamentarium: Hot Topics From the Science ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Prior Treatment Options and Outcomes for SD - MD Magazine - November 18th, 2023 [November 18th, 2023]
- Consequences of Lying on the Witness Stand: Are There Any for Dermatology Expert Witnesses? - Dermatology Times - October 27th, 2023 [October 27th, 2023]
- The Cutaneous Manifestations of Drug Reactions Can Mimic Traumatic Injuries: Case Reports and the Potential Role ... - Cureus - October 27th, 2023 [October 27th, 2023]
- Robyn Siperstein, MD, FAAD: Initiating a Patient-First Dialogue in ... - Dermatology Times - October 27th, 2023 [October 27th, 2023]
- Tralokinumab May Improve 52-Week Outcomes in Patients With Moderate to Severe Atopic Dermatitis - Dermatology Advisor - October 27th, 2023 [October 27th, 2023]
- How to Safely and Effectively Exfoliate Your Skin, According to Dermatologists - Allure - October 27th, 2023 [October 27th, 2023]
- Enhancing the Patient Experience Through Addressing Pain Points ... - Dermatology Times - October 27th, 2023 [October 27th, 2023]
- Global Dermatology Collaboration and Licensing Deals and Agreements Analysis Report 2023 with Directory of Dermatology Deal Records Signed Since 2016... - October 27th, 2023 [October 27th, 2023]
- UNION therapeutics to present at 7th Annual Dermatology Drug ... - PR Newswire - October 27th, 2023 [October 27th, 2023]
- Tareen Dermatology Expands to Hudson, Wisconsin, Adding Sixth Location within the Hudson Medical Center - Yahoo Finance - October 27th, 2023 [October 27th, 2023]
- 4 Tips and Considerations for Selecting a Systemic Treatment for ... - Dermatology Times - October 27th, 2023 [October 27th, 2023]
- Yales Richard Edelson on what got him started in research for ... - The Cancer Letter - October 27th, 2023 [October 27th, 2023]